| Title |
The Safety of Melatonin in Humans
|
|---|---|
| Published in |
Clinical Drug Investigation, December 2015
|
| DOI | 10.1007/s40261-015-0368-5 |
| Pubmed ID | |
| Authors |
Lars Peter Holst Andersen, Ismail Gögenur, Jacob Rosenberg, Russel J. Reiter |
| Abstract |
Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review was to present and evaluate the literature concerning the possible adverse effects and safety of exogenous melatonin in humans. Furthermore, we provide recommendations concerning the possible risks of melatonin use in specific patient groups. In general, animal and human studies documented that short-term use of melatonin is safe, even in extreme doses. Only mild adverse effects, such as dizziness, headache, nausea and sleepiness have been reported. No studies have indicated that exogenous melatonin should induce any serious adverse effects. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 25% |
| Iran, Islamic Republic of | 1 | 8% |
| Dominican Republic | 1 | 8% |
| India | 1 | 8% |
| Kuwait | 1 | 8% |
| Unknown | 5 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 330 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 328 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 40 | 12% |
| Student > Master | 38 | 12% |
| Other | 33 | 10% |
| Student > Ph. D. Student | 27 | 8% |
| Student > Bachelor | 27 | 8% |
| Other | 57 | 17% |
| Unknown | 108 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 83 | 25% |
| Agricultural and Biological Sciences | 17 | 5% |
| Biochemistry, Genetics and Molecular Biology | 16 | 5% |
| Nursing and Health Professions | 16 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 5% |
| Other | 62 | 19% |
| Unknown | 120 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 148. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2024.
All research outputs
#282,708
of 25,718,113 outputs
Outputs from Clinical Drug Investigation
#6
of 1,042 outputs
Outputs of similar age
#4,567
of 398,007 outputs
Outputs of similar age from Clinical Drug Investigation
#1
of 12 outputs
Altmetric has tracked 25,718,113 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,042 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,007 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.